H eart failure (HF) has become a major global epidemic, with increasing prevalence, clinical impact, and cost, with approximately half because of diastolic dysfunction; commonly referred to as HF with preserved ejection fraction (HFpEF). [1] [2] [3] Beyond its effects on mortality, HF, regardless of its type, can also have a profound impact on patients' health status-their symptoms, function, and quality of life (QOL). To date, however, there have been no established methods for reliably and validly quantifying the health status of patients with HFpEF. Understanding the health status outcomes of HFpEF from patients' perspectives is especially important to accurately assess the success of treatment, both in clinical trials and routine care.
Methods

Patient Population
Patients were drawn from the Washington University Heart Failure Registry, a prospective registry of inpatients and outpatients carrying a clinical diagnosis of HF, regardless of EF or pathogenesis, evaluated at Washington University School of Medicine or Barnes-Jewish Hospital, St Louis, MO. Detailed patient information was prospectively collected, including heart disease onset, pathogenesis, clinical stage and severity, medications, device therapies, comorbidities, demographics, and health status. All patients provided informed consent, and the study was approved by the Washington University Institutional Review Board.
Study Measures
Patients were assessed for clinical factors and health status at the time of study enrollment or baseline, and subsequent clinical outcomes were collected at 6, 12, 18, and 24 months. Disease-specific health status was assessed with the KCCQ, 11 a 23-item, self-administered questionnaire that quantifies multiple domains by which HF can impact patients' lives, including their physical and social limitations, symptom frequency and severity, QOL, recent changes in symptom status, and self-efficacy. The first 4 domains can be combined into an overall summary scale, which has previously been shown to be valid, reliable, sensitive to clinical change and associated with survival, hospitalization, and costs in patients with HFrEF. 8, 9, 11, [15] [16] [17] [18] [19] Values for all domains range from 0 to 100, with higher scores indicating lower symptom burden and better QOL. Scores were divided into ranges of 0 to 25, 26 to 50, 51 to 75, and 76 to 100, which corresponds to severe, moderate, fair, and little-to-no disability, respectively. 7, 11, 20 New York Heart Association Functional Class, a physician-assigned assessment of patients' symptoms and function, was also recorded for each patient at baseline.
Measuring Clinical Outcomes and Follow-Up
Clinical outcomes after enrollment were collected by telephone interviews at home or in-person interviews at clinic visits. These were supplemented with medical record reviews at 6, 12, 18, and 24 months. For patients who were unreachable by telephone and did not have any documentation of contact in their medical record, vital status was determined with the social security death index. Data collected for each clinical event included date and reason for death and hospitalization(s), categorized as one of the following: HF, other cardiac, or noncardiac reason for admission.
Definition of HFpEF
The EF used to differentiate HFpEF from HFrEF is variably defined as >40%, >45%, or >50% in the medical literature. [21] [22] [23] [24] [25] Given the uncertainty of how to classify patients with an EF between 40% and 50%, our primary analysis was designed to focus on groups in whom there would be no controversy about the classification of their HF. Therefore, we considered HFrEF as those with an EF<40% and compared the performance of the KCCQ with those with HFpEF, defined as an EF≥50%. A sensitivity analysis was performed to determine whether the definition of HFpEF used above may have biased the data analysis. Therefore, we repeated the analysis with HFpEF defined as EF>40%. We also examined the relationship between KCCQ and NYHA among intermediate EF patients (EF=41%-49%). EF was obtained from chart review, using the most recent echocardiogram, nuclear scan, ventriculogram, or cardiac MRI performed before the health status assessment.
Statistical Methods
In the primary analysis, patients were grouped into HFrEF (EF≤40%) and HFpEF (EF≥50%). In the supplementary analysis, patients were analyzed as EF greater or less than 40%. Patients who did not complete the KCCQ were excluded from the analysis (32 [13.8%] of 232 patients with HFpEF and 116 [12%] or 965 patients with HFrEF). Among the 28 variables listed in Table 1 , there were no significant differences between HFpEF patients who did and did not complete the health status assessments, except that those who participated in this study were more likely to be taking β-blockers (87% versus 69%; P=0.01) and less likely to have had a previous history of cerebrovascular disease (10% versus 29%; P=0.01). Descriptive statistics were provided for patient characteristics by EF group. Student t tests for independent groups and Fisher exact tests were used to compare continuous and categorical data, respectively. All statistical analyses were performed with the use of SAS software, version 9.2 (SAS Institute, Inc, Cary, NC).
Internal Reliability of the KCCQ
Cronbach's α was used to determine the internal consistency of the KCCQ domains among patients with HFrEF and HFpEF, separately. Cronbach's α evaluates the internal consistency, or the average correlation, of the items within a domain. 26 Values range from 0 to 1 with larger values providing greater consistency of the items within the scale.
Criterion Validity of the KCCQ in HFpEF
The KCCQ overall summary and total symptoms domains were compared across categories of NYHA functional class. Spearman rankorder correlations were used to describe the overall trend between KCCQ and NYHA. To examine whether or not the association between KCCQ and NYHA differed between those with HFpEF and HFrEF, a 2-way ANOVA with a test for the interaction by type of HF was performed.
Predictive Validity of the KCCQ in Patients With HFpEF
To assess the prognostic ability of the KCCQ, patients were followed from the date of enrollment until date of death or first hospitalization, up to 2 years. Kaplan-Meier (KM) curves were created for the composite of death and all-cause hospitalization by KCCQ overall summary scores category: 0 to 25, 26 to 50, 51 to 75, and 76 to 100. KM estimates for 1-year event-free rates were provided for patients with HFrEF and HFpEF, and the log-rank test was used to identify differences in survival distributions. KM curves were also created for death, all-cause hospitalization, and hospitalization for HF separately.
A Cox proportional hazards model evaluated the association of KCCQ overall summary scores (as a continuous variable) at enrollment, whereas adjusting for age, body mass index, race, sex, inpatient/outpatient status at time of enrollment, HF pathogenesis, history of atrial fibrillation or atrial flutter, diabetes mellitus, smoking status, and EF group. The interaction between KCCQ and EF group was also included to determine whether the association between KCCQ and the time until death or hospitalization varied with respect to type of HF (HFpEF versus HFrEF). While adjusting for the same covariates, a separate Cox regression model examined the relationship between death or hospitalization and KCCQ overall summary score when categorized into ranges (0-25, 26-50, 51-75, and 76-100), including an interaction term for KCCQ category and EF group. The c-statistic for KCCQ overall summary score as a predictor of death or hospitalization was calculated for HFrEF and HFpEF separately. The c-statistic evaluates the discriminatory ability of the KCCQ to differentiate events and nonevents. 27 Because inpatients with HF tend to have rapidly changing symptoms, there is a potential risk for variable responses depending on the understanding of patients completing the KCCQ. To determine whether the predictive ability of the KCCQ differed with respect to inpatient/outpatient status, a separate multivariable Cox model was created that included an interaction term for KCCQ and inpatient/ outpatient status, along with the same adjustment variables as before.
Supplementary Analysis
To evaluate the sensitivity of EF cut point when defining HFpEF, EF≤40% versus EF>40%, thereby including those with an EF between 40% and 50%, was evaluated in a similar fashion as the primary analysis above. In addition, the KCCQ overall summary score and total symptoms score were examined by NYHA class for HFrEF (EF≤40) versus intermediate (EF=41-49) versus HFpEF (EF≥50) using a 2-way ANOVA with interaction.
Results
For the primary analysis, there were 849 patients available for analysis, of which 200 (24%) were identified as having HFpEF (EF≥50%) and 649 (76%) with HFrEF (EF≤40%). Participants were enrolled between March 2010 and September 2012, providing an average follow-up time of 16.6±6.7 months. Table 1 contains detailed patient characteristics and comparisons between patients with HFrEF and HFpEF. Consistent with previous literature, patients with HFpEF were older, had higher blood pressure, and a greater proportion of women as compared with patients with HFrEF. 28 The median time between EF assessment and enrollment in the study was ≈4 months with an interquartile range of 11 months. There were minimal amounts of missing data with only 6.7% missing ≥1 baseline characteristics. The most frequently missing variable was smoking status, which was missing in 2% of the patients. Missing data variables are listed in Table I in the online-only Data Supplement.
Internal Reliability of the KCCQ in HFpEF
In patients with HFpEF, the internal consistency assessed with Cronbach's α of each KCCQ domain was good to excellent (α>0.80), and acceptable in the self-efficacy domain (α=0.69). This pattern was mirrored among patients with HFrEF (Table 2) , and there were minimal differences in the internal consistency of the KCCQ domains between the 2 populations.
Criterion Validity of the KCCQ in HFpEF
As shown in Table 3 and Figure 1 , KCCQ overall summary scores were highly correlated to NYHA class for both HFrEF (r=−0.55; P<0.001) and HFpEF (r=−0.62; P<0.001), with large and statistically significant differences in mean KCCQ overall summary scores between NYHA classes in both groups. No significant interaction (P=0.27) was identified between HF type and NYHA class, suggesting that the association between NYHA and KCCQ overall summary score is similar in patients with HFrEF and HFpEF. Similarly, the KCCQ total symptoms domain scores were highly correlated to NYHA class, (patients with HFpEF: r=−0.61; P<0.001 and patients with HFrEF: r=−0.54; P<0.001), with no significant interaction between HFpEF and HFrEF; P=0.20 (Table 4 ).
Predictive Validity of the KCCQ in HFpEF
During the study period, there were 469 adverse events (deaths or hospitalizations), 391 events in 621 patients with HFrEF (63% of cohort), and 78 events in 188 patients with HFpEF (41% of cohort). As this is an ongoing registry, there were 40 recently enrolled subjects for whom no follow-up information was available at the time of analysis (28 with HFrEF and 12 with HFpEF). Lower KCCQ overall summary scores at enrollment were associated with lower event-free survival rates than higher KCCQ summary scores (P<0.001) for patients with HFpEF, as well as for the entire study cohort (Figure 2 ). Among patients with HFpEF, the KMestimated 1-year event-free survival rates by KCCQ score quartile were KCCQ 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (Table 4 ). After multivariable adjustment, KCCQ overall summary scores were significantly associated with time until death or hospitalization, a 10-point increase in KCCQ overall summary score resulted in a 12% decrease in the hazard of death/hospitalization (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.81-0.96). A similar association was found among patients with HFrEF (HR, 0.84 per 10-point higher KCCQ score; 95% CI, 0.81-0.88), with no significant interaction between HFpEF and KCCQ (P=0.37).
Analyzing KCCQ as a categorical variable, patients with HFpEF with KCCQ summary scores of 0 to 25 had a 3-fold greater risk of death/hospitalization as compared with patients with scores 76 to 100 (adjusted HR, 3.15; 95% CI, 1.62-6.15). Risk decreased as KCCQ score ranges increased, although the differences were not statistically significant (KCCQ 26-50; adjusted HR, 1.41; 95% CI, 0.79-2.52 and KCCQ 51 to 75; adjusted HR, 1.04; 95% CI, 0.55-1.96; Figure 3 ). The c-statistic for KCCQ as a predictor of death or hospitalization was comparable between types of HF (HFrEF, 0.69; 95% CI, 0.65-0.73 and HFpEF, 0.67; 95% CI, 0.59-0.76).
When examining the outcomes individually, there were 105 deaths (HFrEF, 96; HFpEF, 9) and 442 all-cause hospitalizations (HFrEF, 368; HFpEF, 74). There were significant differences across KCCQ score ranges for both individual end points (log-rank P<0.05 for both death and all-cause hospitalization for patients with HFrEF and HFpEF; Table 4 ).
We found that the association of KCCQ and outcome did not vary with respect to inpatient/outpatient enrollment status (P value for interaction=0. 0.21). Among outpatients that were admitted during the study period (n=369), the median time to admission after KCCQ administration was 5 months (interquartile range, 8 months) Among all outpatients in the cohort, the KM follow-up period was ≈16 months.
Supplementary Analyses
Adding the patients with intermediate EF and dichotomizing the total sample n=940 into those with HFrEF (EF≤40) versus HFpEF (EF>40), the number of patients with HFpEF increased to n=291 (31%). The above analyses were repeated, and the results were consistent with the primary analyses 
Discussion
Given the growing importance of understanding the impact of disease on patients' perceptions of their health status, 6, 9, 10, 16 and the increasing prevalence of HFpEF, 22, 23 there is a pressing need to have a validated measure for quantifying health status in this population. In this study, we investigated several standard psychometric properties of the KCCQ, which was originally developed for patients with HFrEF, in patients with HFpEF. Using data from a prospective HF registry, we found similar criterion validity, as assessed by the associations between the KCCQ NYHA class functional, and similar internal reliability in patients with HFpEF and HFrEF. We also noted similar predictive validity, with lower KCCQ scores being associated with worse event-free survival (all-cause death and HF hospitalization) at 1 year. Moreover, the sensitivity analyses suggested that the KCCQ reliably predicted clinical outcomes in patients across all EF spectra. Viewed together, these results provide important preliminary evidence that the KCCQ has similar psychometric properties across a broad spectrum of patients with HF, regardless of patients' EF.
Approximately half of hospitalizations in the United States for the clinical syndrome of HF occur in patients with a preserved or normal EF, and the incidence of hospitalization in this patient group has been steadily increasing during the past 2 decades. 1, [29] [30] [31] Unfortunately, no treatment options have been proven to reduce mortality in HFpEF. 32, 33 To improve the care of patients with HFpEF, a means of monitoring the impact of the disease on their health status is needed to supplement the traditional outcomes of hospitalization and mortality. Although it is tempting to use measures validated in the HFrEF population, patients with HFpEF have distinct pathophysiology and comorbidities. In fact, controversy exists over whether the disease is part of a continuum with HFrEF, possesses a unique pathophysiology, or is a group of diverse disorders each of which lead to the clinical syndrome of HF. 22, 23, 34 Patients with HFpEF are more likely to be of an older age, female, and hypertensive, and they are less likely to have coronary artery disease compared with patients with HFrEF. For these reasons, extrapolation from established HFrEF metrics to the HFpEF population without previous validation may be inappropriate.
The goal of this study was to evaluate a potential measure, the KCCQ, for evaluating disease status and progression in HFpEF. Given that the HFpEF is primarily defined by the same symptom complex as HFrEF, we anticipated that the KCCQ, which measures patients' health status from their perspectives, would be equally valid in HFpEF as it is in HFrEF. Finding virtually identical psychometric properties of the KCCQ in both populations of patients with HF suggests that the KCCQ can be used to measure patients' health status in HFpEF. The availability of a tool to measure health status in patients with HFpEF is important in light of increasing evidence suggesting that QOL may be of equally great, or even greater, importance to some patients than decreased mortality, particularly in older patients with HF. [35] [36] [37] As such, QOL is increasingly recognized as a key end point in recent HF studies, especially in older adults, 33, 38, 39 and was recently found to be valid in a cohort of patients with aortic stenosis undergoing transcutaneous aortic valve replacement. 40 In addition, because the mortality rate in HFpEF is probably lower than that in HFrEF, 1, 41, 42 a valid measure of health status and QOL will greatly decrease the time required for clinical trials to assess for meaningful treatment effects, further facilitating clinical investigation.
Although it has been shown that symptom burden and QOL are equally impaired in HFpEF as in HFrEF, 32, [43] [44] [45] little is known about the validity and prognostic ability of existing HF status questionnaires in HFpEF. Nevertheless, even in the absence of such data, ongoing large randomized clinical studies in HFpEF, such as the National Institutes of Health funded, multicenter trial, Treatment Of Preserved Cardiac function heart failure with an Aldosterone antagonist (TOPCAT), are using disease-specific QOL questionnaires as metrics of disease progress. 33 Our findings support the use of the KCCQ in TOPCAT and suggest that it can fill the pressing need for an established metric of disease progression in HFpEF. Once this study is completed, additional data supporting the validity, reliability, predictive validity, responsiveness, and interpretability of the KCCQ in HFpEF will be available.
Our results should be interpreted in the context of the following potential limitations. First, in this registry, the KCCQ was administered only at initial enrollment. Thus, there was no serial testing for test-retest reliability, nor was there the explicit demonstration of responsiveness to clinical change. Future studies will need to address this persistent gap in psychometric evaluation of the KCCQ for patients with HFpEF. Second, this was a single-center study. However, there was a good representation of women and minorities, and there are no a priori reasons to expect that patients with HFpEF at Washington University would differ in their responses to the KCCQ compared with patients at other institutions. Finding similar performance at our center in patients with HFrEF with those reported in the literature further adds to the generalizability of our findings. Next, we did not perform formal, qualitative solicitations of patients' symptoms, and there may be additional domains relevant to the assessment of patient-reported outcomes in patients with HFpEF. Regardless, those domains that were measured in the KCCQ showed excellent validation, internal reliability, and prognostic significance, suggesting that they are relevant and important to patients with HFpEF. Future studies may seek to explore whether other domains ought to be assessed to further improve the content validity of the KCCQ in patients with HFpEF. An additional concern would be the inclusion of patients with acutely decompensated HF who may have had difficulty reflecting on the 2-week recall period of the KCCQ. Finding evidence of the criterion and predictive validity, despite this potential limitation, and no difference between inpatients and outpatients suggests that the KCCQ may perform well in clinical trials or quality assessment among hospitalized patients with HFpEF. Finally, exercise capacity was not measured in the study, nor was there a comparison with additional QOL instruments; thus, we could not more reliably measure convergent validity in this study. However, the extensive previous analyses to establish convergent validity in HFrEF and the similarity of the association of the KCCQ with NYHA and prognosis suggest that the KCCQ is likely going to have similar convergent validity in patients with HFpEF as well. This needs to be established in future registries or clinical trials, such as TOPCAT.
Conclusions
The results of this study suggest that the KCCQ is a valid and reliable instrument to measure health status and QOL in patients with HFpEF, with virtually identical performance characteristics as previously observed in patients with HFrEF. Although future studies are needed to replicate and extend our findings, including the establishment of the instrument's responsiveness in HFpEF, our preliminary findings suggest that the KCCQ represents a potentially important research and clinical tool to measure disease status in all patients with HF.
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